Jan 31, 2022 7:59am EST NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules
Jan 27, 2022 6:51am EST NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant
Jan 26, 2022 6:51am EST NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge
Jan 18, 2022 6:48am EST NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments
Jan 12, 2022 5:48pm EST NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics
Jan 11, 2022 7:54am EST NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron Variant
Jan 07, 2022 5:49pm EST NRx Pharmaceuticals to Announce New Details for Planned Investigational BriLife™ COVID-19 Vaccine
Jan 07, 2022 6:48am EST NRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright BioConnect Virtual Conference
Jan 05, 2022 6:48am EST NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
